ARTICLE | Clinical News
Signifor pasireotide regulatory update
November 12, 2012 8:00 AM UTC
FDA's Endocrinologic and Metabolic Drugs Advisory committee voted 10-0 that efficacy and safety data for pasireotide from Novartis support approval to treat Cushing's disease. Novartis submitted the a...